New aspects in photodynamic therapy of actinic keratoses

Journal of Photochemistry and Photobiology B: Biology

Volumn 96, Issue 3, 2009, Pages 159-169

  Smits, Tim ^a   Moor, Anne C E ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Photonamic GmbH and Co KG   (Germany)

Author keywords

5 Aminolevulinic acid; Actinic keratosis; Methyl aminolevulinate; Photodynamic therapy; Protoporphyrin IX

Indexed keywords

1,2 DIETHYL 3 HYDROXY 4 PYRIDONE; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; ANALGESIC AGENT; CAPSAICIN; KERASTICK; LIDOCAINE; MORPHINE; PLACEBO; PRILOCAINE; PROTOPORPHYRIN; TETRACAINE; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; APPLICATION SITE BURNING; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; APPLICATION SITE SCABBING; BASAL CELL CARCINOMA; BURNING SENSATION; CHEMOLUMINESCENCE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CRYOSURGERY; DISEASE CLASSIFICATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; EDEMA; ERYTHEMA; HUMAN; HYPOPIGMENTATION; ILLUMINATION; PAIN; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PREVALENCE; PRIORITY JOURNAL; PRURITUS; REVIEW; RISK FACTOR; STRATUM CORNEUM; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT RESPONSE;

AMINOLEVULINIC ACID; HUMANS; KERATOSIS, ACTINIC; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS;

EID: 68749083285     PISSN: 10111344     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jphotobiol.2009.06.003     Document Type: Review

References (132)

1. Ortonne J.P. From actinic keratosis to squamous cell carcinoma. Brit. J. Dermatol. 146 Suppl. 61 (2002) 20-23
2. Schwartz R.A. Premalignant keratinocytic neoplasms. J. Am. Acad. Dermatol. 35 (1996) 223-242
3. Harvey I., Frankel S., Marks R., Shalom D., and Nolan-Farrell M. Non-melanoma skin cancer and solar keratoses. I. Methods and descriptive results of the South Wales skin cancer study. Brit. J. Cancer 74 (1996) 1302-1307
4. Marks R., Rennie G., and Selwood T.S. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1 (1988) 795-797
5. Callen J.P., Bickers D.R., and Moy R.L. Actinic keratoses. J. Am. Acad. Dermatol. 36 (1997) 650-653
6. Dodson J.M., DeSpain J., Hewett J.E., and Clark D.P. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch. Dermatol. 127 (1991) 1029-1031
7. Marks R., Foley P., Goodman G., Hage B.H., and Selwood T.S. Spontaneous remission of solar keratoses the case for conservative management. Brit. J. Dermatol. 115 (1986) 649-655
8. Marks R. Who benefits from calling a solar keratosis a squamous cell carcinoma?. Brit. J. Dermatol. 155 (2006) 23-26
9. Ackerman A.B., and Mones J.M. Solar (actinic) keratosis is squamous cell carcinoma. Brit. J. Dermatol. 155 (2006) 9-22
10. Yantsos V.A., Conrad N., Zabawski E., and Cockerell C.J. Incipient intraepidermal cutaneous squamous cell carcinoma a proposal for reclassifying and grading solar (actinic) keratoses. Semin. Cutan. Med. Surg. 18 (1999) 3-14
11. Scurry J. Grading of actinic keratoses. J. Am. Acad. Dermatol. 44 (2001) 1052-1053
12. Rowert-Huber J., Patel M.J., Forschner T., Ulrich C., Eberle J., Kerl H., Sterry W., and Stockfleth E. Actinic keratosis is an early in situ squamous cell carcinoma a proposal for reclassification. Brit. J. Dermatol. 156 Suppl. 3 (2007) 8-12
13. Stockfleth E., and Kerl H. Guideline Subcommittee of the European dermatology forum, guidelines for the management of actinic keratoses. Eur. J. Dermatol. 16 (2006) 599-606
14. de Berker D., McGregor J.M., and Hughes B.R. British association of dermatologists therapy guidelines and audit subcommittee, guidelines for the management of actinic keratoses. Brit. J. Dermatol. 156 (2007) 222-230
15. Kennedy J.C., Pottier R.H., and Pross D.C. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J. Photochem. Photobiol. B 6 (1990) 43-148
16. C.A. Morton, S.B. Brown, S. Collins, S. Ibbotson, H. Jenkinson, H. Kurwa, K. Langmack, K. McKenna, H. Moseley, A.D. Pearse, M. Stringer, D.K. Taylor, G. Wong, L.E. Rhodes, Guidelines for topical photodynamic therapy: report of a workshop of the British photodermatology group, Brit. J. Dermatol. 146 (2002) 552-567.
17. M.S. Nestor, M.H. Gold, A.N. Kauvar, A.F. Taub, R.G. Geronemus, E.C. Ritvo, M.P. Goldman, D.J. Gilbert, D.F. Richey, T.S. Alster, R.R. Anderson, D.E. Bank, A. Carruthers, J. Carruthers, D.J. Goldberg, C.W. Hanke, N.J. Lowe, D.M. Pariser, D.S. Rigel, P. Robins, J.M. Spencer, B.D. Zelickson, The use of photodynamic therapy in dermatology: results of a consensus conference, J. Drug. Dermatol. 5 (2006) 140-154.
18. L.R. Braathen, R.M. Szeimies, N. Basset-Seguin, R. Bissonnette, P. Foley, D. Pariser, R. Roelandts, A.M. Wennberg, C.A. Morton, International society for photodynamic therapy in dermatology, guidelines on the use of photodynamic therapy for nonmelanoma skin cancer an international consensus, international society for photodynamic therapy in dermatology 2005, J. Am. Acad. Dermatol. 56 (2007) 125-143.
19. C.A. Morton, K.E. McKenna, L.E. Rhodes, British association of dermatologists therapy guidelines and audit subcommittee and the British photodermatology group, guidelines for topical photodynamic therapy update, Brit. J. Dermatol. 159 (2008) 1245-1266.
20. Ormrod D., and Jarvis B. Topical aminolevulinic acid HCl photodynamic therapy. Am. J. Clin. Dermatol. 1 (2000) 133-139
21. Jeffes E.W. Levulan the first approved topical photosensitizer for the treatment of actinic keratosis. J. Dermatol. Treat. 13 Suppl. 1 (2002) S19-S23
22. Piacquadio D.J., Chen D.M., Farber H.F., Fowler Jr J.F., Glazer S.D., Goodman J.J., Hruza L.L., Jeffes E.W., Ling M.R., Phillips T.J., Rallis T.M., Scher R.K., Taylor C.R., and Weinstein G.D. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch. Dermatol. 140 (2004) 41-46
23. Tschen E.H., Wong E.H., Pariser D.S., Dunlap D.M., Houlihan F.E., and Ferdon A. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp phase IV multicentre clinical trial with 12-month follow. Brit. J. Dermatol. 155 (2006) 1262-1269
24. Smith S., Piacquadio D., Morhenn V., Atkin D., and Fitzpatrick R. Short incubation PDT versus 5-FU in treating actinic keratoses. J. Drugs Dermatol. 2 (2003) 629-635
25. Touma D., Yaar M., Whitehead S., Konnikov N., and Gilchrest B.A. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch. Dermatol. 140 (2004) 33-40
26. ®. (accessed 30.01.09).
27. Lehmann P. Methyl aminolaevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. Brit. J. Dermatol. 156 (2007) 793-801
28. Stritt A., Merk H.F., Braathen L.R., and von Felbert V. Photodynamic therapy in the treatment of actinic keratosis. Photochem. Photobiol. 84 (2008) 388-398
29. Tarstedt M., Rosdahl I., Berne B., Svanberg K., and Wennberg A.M. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Dermatol. Venereol. 85 (2005) 424-428
30. Pariser D.M., Lowe N.J., Stewart D.M., Jarratt M.T., Lucky A.W., Pariser R.J., and Yamauchi P.S. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J. Am. Acad. Dermatol. 48 (2003) 227-232
31. Freeman M., Vinciullo C., Francis D., Spelman L., Nguyen R., Fergin P., Thai KE K.E., Murrell D., Weightman W., Anderson C., Reid C., Watson A., and Foley P. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J. Dermatol. Treat. 14 (2003) 99-106
32. Pariser D., Loss R., Jarratt M., Abramovits W., Spencer J., Geronemus R., Bailin P., and Bruce S. Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: a randomized, double-blind, placebo-controlled study. J. Am. Acad. Dermatol. 59 (2008) 569-576
33. Szeimies R.M., Karrer S., Radakovic-Fijan S., Tanew A., Calzavara-Pinton P.G., Zane C., Sidoroff A., Hempel M., Ulrich J., Proebstle T., Meffert H., Mulder M., Salomon D., Dittmar H.C., Bauer J.W., Kernland K., and Braathen L. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J. Am. Acad. Dermatol. 47 (2002) 258-262
34. Morton C., Campbell S., Gupta G., Keohane S., Lear J., Zaki I., Walton S., Kerrouche N., Thomas G., and Soto P. AKtion investigators, intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Brit. J. Dermatol. 155 (2006) 1029-1036
35. Kaufmann R., Spelman L., Weightman W., Reifenberger J., Szeimies R.M., Verhaeghe E., Kerrouche N., Sorba V., Villemagne H., and Rhodes L.E. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Brit. J. Dermatol. 158 (2008) 994-999
36. Fink-Puches R., Hofer A., Smolle J., Kerl H., and Wolf P. Primary clinical response and long-term follow-up of solar keratoses treated with topically applied 5-aminolevulinic acid and irradiation by different wave bands of light. J. Photochem. Photobiol. B 41 (1997) 145-151
37. Szeimies R.M., Karrer S., Sauerwald A., and Landthaler M. Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Dermatology 192 (1996) 246-251
38. Kurwa H.A., Yong-Gee S.A., Seed P.T., Markey A.C., and Barlow R.J. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J. Am. Acad. Dermatol. 41 (1999) 414-418
39. ®. (accessed 30.01.09).
40. Adami J., Gäbel H., Lindelöf B., Ekström K., Rydh B., Glimelius B., Ekbom A., Adami H.O., and Granath F. Cancer risk following organ transplantation a nationwide cohort study in Sweden. Brit. J. Cancer 689 (2003) 1221-1227
41. Dragieva G., Hafner J., Dummer R., Schmid-Grendelmeier P., Roos M., Prinz B.M., Burg G., Binswanger U., and Kempf W. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 1577 (2004) 115-121
42. Wulf H.C., Pavel S., Stender I., and Bakker-Wensveen C.A. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Dermatol. Venereol. 86 (2006) 25-28
43. Piaserico S., Belloni Fortina A., Rigotti P., Rossi B., Baldan N., Alaibac M., and Marchini F. Topical photodynamic therapy of actinic keratosis in renal transplant recipients. Transplant. Process. 39 (2007) 1847-1850
44. Bissonnette R. Chemopreventative thoughts for photodynamic therapy. Dermatol. Clin. 25 (2007) 95-100
45. de Graaf Y.G., Kennedy C., Wolterbeek R., Collen A.F., Willemze R., and Bouwes Bavinck J.N. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients results of a randomized-controlled trial. J. Invest. Dermatol. 126 (2006) 569-574
46. Wennberg A.M., Stenquist B., Stockfleth E., Keohane S., Lear J.T., Jemec G., Mork C., Christensen E., Kapp A., Solvsten H., Talme T., Berne B., and Forschner T. Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study. Transplantation 1586 (2008) 423-429
47. Sandberg C., Stenquist B., Rosdahl I., Ros A.M., Synnerstad I., Karlsson M., Gudmundson F., Ericson M.B., Larkö O., and Wennberg A.M. Important factors for pain during photodynamic therapy for actinic keratosis. Acta Dermatol. Venereol. 86 (2006) 404-408
48. Wiegell S.R., Stender I.M., Na R., and Wulf H.C. Pain associated with photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-stripped normal skin. Arch. Dermatol. 139 (2003) 1173-1177
49. Kasche A., Luderschmidt S., Ring J., and Hein R. Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid. J. Drug. Dermatol. 5 (2006) 353-356
50. Rud E., Gederaas O., Høgset A., and Berg K. 5-aminolevulinic acid, but not 5-aminolevulinic acid esters, is transported into adenocarcinoma cells by system beta transporters. Photochem. Photobiol. 71 (2000) 640-647
51. Hürlimann A.F., Hänggi G., and Panizzon R.G. Photodynamic therapy of superficial basal cell carcinomas using topical 5-aminolevulinic acid in a nanocolloid lotion. Dermatology 197 (1998) 248-254
52. Wang I., Bauer B., Andersson-Engels S., Svanberg S., and Svanberg K. Photodynamic therapy utilising topical delta-aminolevulinic acid in non-melanoma skin malignancies of the eyelid and the periocular skin. Acta Ophthalmol. Scand. 77 (1999) 182-188
53. Pagliaro J., Elliott T., Bulsara M., King C., and Vinciullo C. Cold air analgesia in photodynamic therapy of basal cell carcinomas and Bowen's disease an effective addition to treatment: a pilot study. Dermatol. Surg. 30 (2004) 63-66
54. Fritsch C., Stege H., Saalmann G., Goerz G., Ruzicka T., and Krutmann J. Green light is effective and less painful than red light in photodynamic therapy of facial solar keratoses. Photodermatol. Photoimmunol. Photomed. 13 (1997) 181-185
55. Morton C.A., Whitehurst C., Moore J.V., and MacKie R.M. Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. Brit. J. Dermatol. 143 (2000) 767-772
56. Cottrell W.J., Paquette A.D., Keymel K.R., Foster T.H., and Oseroff A.R. Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. Clin. Cancer Res. 1514 (2008) 4475-4483
57. Wiegell S.R., Skiveren J., Philipsen P.A., and Wulf H.C. Pain during photodynamic therapy is associated with protoporphyrin IX fluorescence and fluence rate. Brit. J. Dermatol. 158 158 (2008) 727-733
58. Ericson M.B., Sandberg C., Stenquist B., Gudmundson F., Karlsson M., Ros A.M., Rosén A., Larkö O., Wennberg A.M., and Rosdahl I. Photodynamic therapy of actinic keratosis at varying fluence rates assessment of photobleaching, pain and primary clinical outcome. Brit. J. Dermatol. 151 (2004) 1204-1212
59. Moseley H., Allen J.W., Ibbotson S., Lesar A., McNeill A., Camacho-Lopez M.A., Samuel I.D., Sibbett W., and Ferguson J. Ambulatory photodynamic therapy a new concept in delivering photodynamic therapy. Brit. J. Dermatol. 154 (2006) 747-750
60. Wiegell S.R., Haedersdal M., Philipsen P.A., Eriksen P., Enk C.D., and Wulf H.C. Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses a randomized, controlled, single-blinded study. Brit. J. Dermatol. 158 (2008) 740-746
61. Holmes M.V., Dawe R.S., Ferguson J., and Ibbotson S.H. A randomized, double-blind, placebo-controlled study of the efficacy of tetracaine gel (Ametop) for pain relief during topical photodynamic therapy. Brit. J. Dermatol. 150 (2004) 337-340
62. Langan S.M., and Collins P. Randomized, double-blind, placebo-controlled prospective study of the efficacy of topical anaesthesia with a eutetic mixture of lignocaine 2.5% and prilocaine 2.5% for topical 5-aminolaevulinic acid-photodynamic therapy for extensive scalp actinic keratoses. Brit. J. Dermatol. 154 (2006) 146-149
63. Skiveren J., Haedersdal M., Philipsen P.A., Wiegell S.R., and Wulf H.C. Morphine gel 0.3% does not relieve pain during topical photodynamic therapy: a randomized, double-blind, placebo-controlled study. Acta Dermatol. Venereol. 86 (2006) 409-411
64. Halldin C.B., Paoli J., Sandberg C., Ericson M.B., and Wennberg A.M. Transcutaneous electrical nerve stimulation for pain relief during photodynamic therapy of actinic keratoses. Acta Dermatol. Venereol. 88 (2008) 311-313
65. Paoli J., Halldin C., Ericson M.B., and Wennberg A.M. Nerve blocks provide effective pain relief during topical photodynamic therapy for extensive facial actinic keratoses. Clin. Exp. Dermatol. 33 (2008) 559-564
66. Borelli C., Herzinger T., Merk K., Berking C., Kunte C., Plewig G., and Degitz K. Effect of subcutaneous infiltration anesthesia on pain in photodynamic therapy: a controlled open pilot trial. Dermatol. Surg. 33 3 (2007) 314-318
67. Smits T., Robles C.A., van Erp P.E., van de Kerkhof P.C., and Gerritsen M.J. Correlation between macroscopic fluorescence and protoporphyrin IX content in psoriasis and actinic keratosis following application of aminolevulinic acid. J. Invest. Dermatol. 125 (2005) 833-839
68. Smits T., Kleinpenning M.M., Blokx W.A., van de Kerkhof P.C., van Erp P.E., and Gerritsen M.J. Fluorescence diagnosis in keratinocytic intraepidermal neoplasias. J. Am. Acad. Dermatol. 57 (2007) 824-831
69. Fritsch C., Homey B., Stahl W., Lehmann P., Ruzicka T., and Sies H. Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester. Photochem. Photobiol. 68 (1998) 218-221
70. Fritsch C., Neumann N.J., Ruzicka T., and Lehmann P. Photodiagnostic test procedures. Part 3 Fluorescence diagnosis with delta-aminolaevulinic-acid induced porphyrins (FDAP) in dermatology. Hautarzt 51 (2000) 528-543
71. Fritsch C., Batz J., Bolsen K., Schulte K.W., Zumdick M., Ruzicka T., and Goerz G. Ex vivo application of delta-aminolevulinic acid induces high and specific porphyrin levels in human skin tumors: possible basis for selective photodynamic therapy. Photochem. Photobiol. 66 (1997) 114-118
72. Walters T.R., Gribble T.J., and Schwartz H.C. Synthesis of haem in normal and leukaemic leucocytes. Nature 197 (1963) 1213-1214
73. Navone N.M., Polo C.F., Frisardi A.L., Andrade N.E., and Battle A.M. Heme biosynthesis in human breast cancer-mimetic "in vitro" studies and some heme enzymic activity levels. Int. J. Biochem. 22 (1990) 1407-1411
74. Riesenberg R., Fuchs C., and Kriegmair M. Photodynamic effects of 5-aminolevulinic acid-induced porphyrin on human bladder carcinoma cells in vitro. Eur. J. Cancer 32A (1996) 328-334
75. Krieg R.C., Fickweiler S., Wolfbeis O.S., and Knuechel R. Cell-type specific protoporphyrin IX metabolism in human bladder cancer in vitro. Photochem. Photobiol. 72 (2000) 226-233
76. Gallegos E.R., DeLeón Rodríguez I., Martínez Guzmán L.A., and Pérez Zapata A.J. In vitro study of biosynthesis of protoporphyrin IX induced by delta-aminolevulinic acid in normal and cancerous cells of the human cervix. Arch. Med. Res. 30 (1999) 163-170
77. Fritsch C., Abels C., Goetz A.E., Stahl W., Bolsen K., Ruzicka T., Goerz G., and Sies H. Porphyrins preferentially accumulate in a melanoma following intravenous injection of 5-aminolevulinic acid. Biol. Chem. 378 (1997) 51-57
78. Schick E., Kaufmann R., Rück A., Hainzl A., and Boehncke W.H. Influence of activation and differentiation of cells on the effectiveness of photodynamic therapy. Acta Dermatol. Venereol. 75 (1995) 276-279
79. Washbrook R., Fukuda H., Battle A., and Riley P. Stimulation of tetrapyrrole synthesis in mammalian epithelial cells in culture by exposure to aminolaevulinic acid. Brit. J. Cancer 75 (1997) 381-387
80. Hinnen P., de Rooij F.W., van Velthuysen M.L., Edixhoven A., van Hillegersberg R., Tilanus H.W., Wilson J.H., and Siersema P.D. Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation a study in patients with (pre)malignant lesions of the oesophagus. Brit. J. Cancer 78 (1998) 679-682
81. Krieg R.C., Messmann H., Rauch J., Seeger S., and Knuechel R. Metabolic characterization of tumor cell-specific protoporphyrin IX accumulation after exposure to 5-aminolevulinic acid in human colonic cells. Photochem. Photobiol. 76 (2002) 518-525
82. Boldt D.H. New perspectives on iron an introduction. Am. J. Med. Sci. 318 (1999) 207-212
83. Ortel B., Chen N., Brissette J., Dotto G.P., Maytin E., and Hasan T. Differentiation-specific increase in ALA-induced protoporphyrin IX accumulation in primary mouse keratinocytes. Brit. J. Cancer 77 (1998) 1744-1751
84. Ickowicz Schwartz D., Gozlan Y., Greenbaum L., Babushkina T., Katcoff D.J., and Malik Z. Differentiation-dependent photodynamic therapy regulated by porphobilinogen deaminase in B16 melanoma. Brit. J. Cancer 490 (2004) 1833-1841
85. Sato N., Moore B.W., Keevey S., Drazba J.A., Hasan T., and Maytin E.V. Vitamin D enhances ALA-induced protoporphyrin IX production and photodynamic cell death in 3-D organotypic cultures of keratinocytes. J. Invest. Dermatol. 127 (2007) 925-934
86. Ortel B., Sharlin D., O'Donnell D., Sinha A.K., Maytin E.V., and Hasan T. Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells. Brit. J. Cancer 1887 (2002) 1321-1327
87. Sinha A.K., Anand S., Ortel B.J., Chang Y., Mai Z., Hasan T., and Maytin E.V. Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells. Brit. J. Cancer 2195 (2006) 485-495
88. Smits T., Laarhoven A.I., Staassen A., van Erp P.E., van de Kerkhof P.C., and Gerritsen M.J. Induction of protoporphyrin-IX by aminolaevulinic acid in actinic keratosis, psoriasis and normal skin preferential porphyrin enrichment in differentiated cells. Brit. J. Dermatol. 160 (2009) 849-857
89. Iinuma S., Farshi S.S., Ortel B., and Hasan T. A mechanistic study of cellular photodestruction with 5-aminolaevulinic acid-induced porphyrin. Brit. J. Cancer 70 (1994) 21-28
90. Rittenhouse-Diakun K., Van Leengoed H., Morgan J., Hryhorenko E., Paszkiewicz G., Whitaker J.E., and Oseroff A.R. The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor delta-aminolevulinic acid (ALA). Photochem. Photobiol. 61 (1995) 523-528
91. Moan J., Bech O., Gaullier J.M., Stokke T., Steen H.B., Ma L.W., and Berg K. Protoporphyrin IX accumulation in cells treated with 5-aminolevulinic acid dependence on cell density, cell size and cell cycle. Int. J. Cancer 575 (1998) 134-139
92. Kloek J., Akkermans W., and Beijersbergen van Henegouwen G.M. Derivatives of 5-aminolevulinic acid for photodynamic therapy enzymatic conversion into protoporphyrin. Photochem. Photobiol. 67 (1998) 150-154
93. Peng Q., Moan J., Warloe T., Iani V., Steen H.B., Bjørseth A., and Nesland J.M. Build-up of esterified aminolevulinic-acid-derivative-induced porphyrin fluorescence in normal mouse skin. J. Photochem. Photobiol. B 34 (1996) 95-96
94. Moan J., Ma L.W., and Iani V. On the pharmacokinetics of topically applied 5-aminolevulinic acid and two of its esters. Int. J. Cancer 192 (2001) 139-143
95. Donnelly R.F., Ma L.W., Juzenas P., Iani V., McCarron P.A., Woolfson A.D., and Moan J. Topical bioadhesive patch systems enhance selectivity of protoporphyrin IX accumulation. Photochem. Photobiol. 82 (2006) 670-675
96. von Beckerath M., Juzenas P., Ma L.W., Iani V., Löfgren L., and Moan J. The influence of UV exposure on 5-aminolevulinic acid-induced protoporphyrin IX production in skin. Photochem. Photobiol. 74 (2001) 825-828
97. van den Akker J.T., Holroyd J.A., Vernon D.I., Sterenborg H.J., and Brown S.B. Chronic UVB exposure enhances in vitro percutaneous penetration of 5-aminulevulinic acid in hairless mouse skin. Laser. Surg. Med. 34 (2004) 141-145
98. Ghadially R., Reed J.T., and Elias P.M. Stratum corneum structure and function correlates with phenotype in psoriasis. J. Invest. Dermatol. 107 (1996) 558-564
99. Stringer M.R., Collins P., Robinson D.J., Stables G.I., and Sheehan-Dare R.A. The accumulation of protoporphyrin IX in plaque psoriasis after topical application of 5-aminolevulinic acid indicates a potential for superficial photodynamic therapy. J. Invest. Dermatol. 107 (1996) 76-81
100. Kleinpenning M.M., Smits T., Ewalds E., van Erp P.E., van de Kerkhof P.C., and Gerritsen M.J. Heterogeneity of fluorescence in psoriasis after application of 5-aminolaevulinic acid an immunohistochemical study. Brit. J. Dermatol. 155 (2006) 539-545
101. Jeffes E.W., McCullough J.L., Weinstein G.D., Fergin P.E., Nelson J.S., Shull T.F., Simpson K.R., Bukaty L.M., Hoffman W.L., and Fong N.L. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study. Arch. Dermatol. 133 (1997) 727-732
102. Gerritsen M.J., Smits T., Kleinpenning M.M., van de Kerkhof P.C., and van Erp P.E. Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy. Dermatology 218 (2009) 193-202
103. Donnelly R.F., McCarron P.A., Morrow D.I., Sibani S.A., and Woolfson A.D. Photosensitiser delivery for photodynamic therapy. Part 1: topical carrier platforms. Exp. Opin. Drug. Deliv. 5 (2008) 757-766
104. Campbell S.M., Morton C.A., Alyahya R., Horton S., Pye A., and Curnow A. Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma. Brit. J. Dermatol. 159 (2008) 387-393
105. Pye A., Campbell S., and Curnow A. Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma. J. Cancer Res. Clin. Oncol. 134 (2008) 841-849
106. Gilmore B.F., McCarron P.A., Morrow D.I., Murphy D.J., Woolfson A.D., and Donnelly R.F. In vitro phototoxicity of 5-aminolevulinic acid and its methyl ester and the influence of barrier properties on their release from a bioadhesive patch. Eur. J. Pharm. Biopharm. 63 (2006) 295-309
107. Donnelly R.F., McCarron P.A., Tunney M.M., and Woolfson A.D. Potential of photodynamic therapy in treatment of fungal infections of the mouth, design and characterisation of a mucoadhesive patch containing toluidine blue O. J. Photochem. Photobiol. B. 86 (2007) 59-69
108. Zawislak A.A., McCarron P.A., McCluggage W.G., Price J.H., Donnelly R.F., McClelland H.R., Dobbs S.P., and Woolfson A.D. Successful photodynamic therapy of vulval Paget's disease using a novel patch-based delivery system containing 5-aminolevulinic acid. BJOG 111 (2004) 1143-1145
109. Zawislak A.A., McCarron P.A., McCluggage W.G., Donnelly R.F., Price J.H., McClelland H.R., and Woolfson A.D. Novel bioadhesive patch-type system for photodynamic vulvodynia therapy after delivery of 5-aminolevulinic acid: preliminary evaluation. J. Reprod. Med. 52 (2007) 645-653
110. McCarron P.A., Donnelly R.F., Andrews G.P., and Woolfson A.D. Stability of 5-aminolevulinic acid in novel non-aqueous gel and patch-type systems intended for topical application. J. Pharm. Sci. 94 (2005) 1756-1771
111. McLoone N., Donnelly R.F., Walsh M., Dolan O.M., McLoone S., McKenna K., and McCarron P.A. Aminolaevulinic acid diffusion characteristics in 'in vitro' normal human skin and actinic keratosis: implications for topical photodynamic therapy. Photodermatol. Photoimmunol. Photomed. 24 (2008) 183-190
112. Lieb S., Szeimies R.M., and Lee G. Self-adhesive thin films for topical delivery of 5-aminolevulinic acid. Eur. J. Pharm. Biopharm. 53 (2002) 99-106
113. Fauteck J.D., Ackermann G., Birkel M., Breuer M., Moor A.C., Ebeling A., and Ortland C. Fluorescence characteristics and pharmacokinetic properties of a novel self-adhesive 5-ALA patch for photodynamic therapy of actinic keratoses. Arch. Dermatol. Res. 300 (2008) 53-60
114. Hauschild A., Popp G., Stockfleth E., Meyer K.G., Imberger D., Mohr P., Itschert G., Kaufmann R., Neuber K., Frambach Y., Gollnick H., Brunnert M., Stocker M., Ortland C., and Karrer S. Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch. Exp. Dermatol. 18 (2009) 116-121
115. Hauschild A., Stockfleth E., Popp G., Borrosch F., Brüning H., Dominicus R., Mensing H., Reinhold U., Reich K., Moor A.C., Stocker M., Ortland C., Brunnert M., and Szeimies R.-M. Optimisation of photodynamic therapy with a novel self-adhesive 5-ALA patch Results of two randomised controlled phase III studies. Brit. J. Dermatol. 160 (2009) 1066-1074
116. Babilas P., Kohl E., Maisch T., Bäcker H., Gross B., Branzan A.L., Bäumler W., Landthaler M., Karrer S., and Szeimies R.M. In vitro and in vivo comparison of two different light sources for topical photodynamic therapy. Brit. J. Dermatol. 154 (2006) 712-718
117. Haedersdal M., Togsverd-Bo K., and Wulf H.C. Evidence-based review of lasers, light sources and photodynamic therapy in the treatment of acne vulgaris. J. Eur. Acad. Dermatol. Venereol. 22 (2008) 267-278
118. Ruiz-Rodriguez R., Sanz-Sánchez T., and Córdoba S. Photodynamic photorejuvenation. Dermatol. Surg. 28 (2002) 742-744
119. Dover J.S., Bhatia A.C., Stewart B., and Arndt K.A. Topical 5-aminolevulinic acid combined with intense pulsed light in the treatment of photoaging. Arch. Dermatol. 141 (2005) 1247-1252
120. Gold M.H., Bradshaw V.L., Boring M.M., Bridges T.M., and Biron J.A. Split-face comparison of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone for photodamage. Dermatol. Surg. 32 (2006) 795-801
121. Babilas P., Knobler R., Hummel S., Gottschaller C., Maisch T., Koller M., Landthaler M., and Szeimies R.M. Variable pulsed light is less painful than light-emitting diodes for topical photodynamic therapy of actinic keratosis: a prospective randomized controlled trial. Brit. J. Dermatol. 157 (2007) 111-117
122. Zelickson B., Counters J., Coles C., and Selim M. Light patch preliminary report of a novel form of blue light delivery for the treatment of actinic keratosis. Dermatol. Surg. 31 (2005) 375-378
123. Batchelor R.J., Stables G.I., and Stringer M.R. Successful treatment of scalp actinic keratoses with photodynamic therapy using ambient light. Brit. J. Dermatol. 156 (2007) 779-781
124. Robinson D.J., de Bruijn H.S., Star W.M., and Sterenborg H.J. Dose and timing of the first light fraction in two-fold illumination schemes for topical ALA-mediated photodynamic therapy of hairless mouse skin. Photochem. Photobiol. 77 (2003) 319-323
125. de Bruijn H.S., den v.d.P.-v., Heuvel A., Sterenborg H.J., and Robinson D.J. Fractionated illumination after topical application of 5-aminolevulinic acid on normal skin of hairless mice the influence of the dark interval. J. Photochem. Photobiol. B 185 3 (2006) 184-190
126. Star W.M., van't Veen A.J., Robinson D.J., Munte K., de Haas E.R., and Sterenborg H.J. Topical 5-aminolevulinic acid mediated photodynamic therapy of superficial basal cell carcinoma using two light fractions with a two-hour interval long-term follow-up. Acta Dermatol. Venereol. 86 (2006) 412-417
127. Mosterd K., Thissen M.R., Nelemans P., Kelleners-Smeets N.W., Janssen R.L., Broekhof K.G., Neumann H.A., Steijlen P.M., and Kuijpers D.I. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma results of a randomized controlled trial. Brit. J. Dermatol. 159 (2008) 864-870
128. de Haas E.R., de Vijlder H.C., Sterenborg H.J., Neumann H.A., and Robinson D.J. Fractionated aminolevulinic acid-photodynamic therapy provides additional evidence for the use of PDT for non-melanoma skin cancer. J. Eur. Acad. Dermatol. Venereol. 22 (2008) 426-430
129. de Bruijn H.S., de Haas E.R., Hebeda K.M., van der Ploeg-van den Heuvel A., Sterenborg H.J., Neumann H.A., and Robinson D.J. Light fractionation does not enhance the efficacy of methyl 5-aminolevulinate mediated photodynamic therapy in normal mouse skin. Photochem. Photobiol. Sci. 6 (2007) 1325-1331
130. de Bruijn H.S., Meijers C., van der Ploeg-van den Heuvel A., Sterenborg H.J., and Robinson D.J. Microscopic localisation of protoporphyrin IX in normal mouse skin after topical application of 5-aminolevulinic acid or methyl 5-aminolevulinate. J. Photochem. Photobiol. B. 2192 (2008) 91-97
131. Avram D.K., and Goldman M.P. Effectiveness and safety of ALA-IPL in treating actinic keratoses and photodamage. J. Drug. Dermatol. 3 Suppl. 1 (2004) S36-S39
132. Kim H.S., Yoo J.Y., Cho K.H., Kwon O.S., and Moon S.E. Topical photodynamic therapy using intense pulsed light for treatment of actinic keratosis clinical and histopathologic evaluation. Dermatol. Surg. 31 (2005) 33-36